Audrius Dulskas1,2, Vytautas Gaizauskas3, Inga Kildusiene4, Narimantas Evaldas Samalavicius2,5,6, Giedre Smailyte4,7. 1. Department of Abdominal and General Surgery and Oncology, National Cancer Institute, 1 Santariskiu Str., LT-08406 Vilnius, Lithuania. 2. Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. 3. Department of Abdominal Surgery, Vilnius University Hospital Santaros Clinics, 2 Santariskiu Str., LT-08661 Vilnius, Lithuania. 4. Laboratory of Cancer Epidemiology, National Cancer Institute, LT-08406 Vilnius, Lithuania. 5. Department of Surgery, Klaipeda University Hospital, 41 Liepojos Str., LT-92288 Klaipeda, Lithuania. 6. Health Research and Innovation Science Center, Faculty of Health Sciences Klaipeda University, 84 Herkaus Manto Str., LT-92294 Klaipeda, Lithuania. 7. Institute of Health Sciences, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
Abstract
PURPOSE: In this study, we analyzed the mortality and survival of colorectal cancer patients in Lithuania. METHODS: This was a national cohort study. Population-based data from the Lithuanian Cancer Registry and period analyses were collected. Overall, 20,980 colorectal cancer patients were included. We examined the changes in colorectal cancer mortality and survival rates between 1998 and 2012 according to cancer anatomical sub-sites and stages. We calculated the 5-year relative survival estimates using period analysis. RESULTS: Overall, 20,980 colorectal cancer cases reported from 1998 to 2012 were included in the study. The total number of newly diagnosed colorectal cancers increased from 1998-2002 to 2008-2012 by 12.1%. The highest number of colorectal cancers was localized and increased from 33.9% to 42.0%. The number of cancers with regional metastases and advanced cancers decreased by 11.1% and 15.5%, respectively. An increased number of new cases was observed for almost all colon cancer sub-sites. The overall 5-year relative survival rate increased from 37.9% in 1998-2002 to 51.5% in 2008-2012. We showed an increase in survival rates for all stages and all sub-sites. In the most recent period, patients with a localized disease had a 5-year survival rate of 78.6%, while survival estimates for advanced cancer patients remained low at 6.6%. CONCLUSION: Although survival rates variated in colorectal cancer patients according to disease stages and sub-sites, we showed increased survival rates for all patients.
PURPOSE: In this study, we analyzed the mortality and survival of colorectal cancerpatients in Lithuania. METHODS: This was a national cohort study. Population-based data from the Lithuanian Cancer Registry and period analyses were collected. Overall, 20,980 colorectal cancerpatients were included. We examined the changes in colorectal cancermortality and survival rates between 1998 and 2012 according to cancer anatomical sub-sites and stages. We calculated the 5-year relative survival estimates using period analysis. RESULTS: Overall, 20,980 colorectal cancer cases reported from 1998 to 2012 were included in the study. The total number of newly diagnosed colorectal cancers increased from 1998-2002 to 2008-2012 by 12.1%. The highest number of colorectal cancers was localized and increased from 33.9% to 42.0%. The number of cancers with regional metastases and advanced cancers decreased by 11.1% and 15.5%, respectively. An increased number of new cases was observed for almost all colon cancer sub-sites. The overall 5-year relative survival rate increased from 37.9% in 1998-2002 to 51.5% in 2008-2012. We showed an increase in survival rates for all stages and all sub-sites. In the most recent period, patients with a localized disease had a 5-year survival rate of 78.6%, while survival estimates for advanced cancerpatients remained low at 6.6%. CONCLUSION: Although survival rates variated in colorectal cancerpatients according to disease stages and sub-sites, we showed increased survival rates for all patients.
Entities:
Keywords:
Lithuanian cancer registry; colorectal cancer; colorectal cancer survival; national burden